For business leaders, corporate strategists, and growth-focused teams – this report delivers deep market intelligence, forecasts, segmentation, and competitor insights to guide your decisions through 2034.
How does the forecasted CAGR of the exondys 51 industry compare to other sectors?
The exondys 51 market size has XX (HCAGR) in recent years. It will grow from $XX million in 2024 to $XX million in 2025 at a compound annual growth rate (CAGR) of XX%. The growth in the historic period can be attributed to increased awareness and diagnosis of DMD, favorable government policies, an increase in the prevalence of rare diseases, and increasing prevalence of Duchenne muscular dystrophy.
The exondys 51 market size is expected to see XX (FCAGR) in the next few years. It will grow to $XX million in 2029 at a compound annual growth rate (CAGR) of XX%. The growth in the forecast period can be attributed to the rising burden of Duchenne muscular dystrophy (DMD), the growing number of new drug launches, increasing research and development activities, and the rising disease burden of DMD. Major trends in the forecast period include technological advancements in diagnostic techniques, advancements in mutation-targeted therapies, mutation-suppressing therapies, R&D activities for the development of novel drug therapies, and advancements in gene therapies.
Download Your Free Sample PDF:
https://www.thebusinessresearchcompany.com/sample.aspx?id=20071&type=smp
What market trends are acting as primary growth drivers for the exondys 51 sector?
The rising burden of genetic disorders is expected to propel the growth of the exondys 51 market going forward. Genetic disorders refer to conditions that are caused by abnormalities or mutations in an individual’s DNA or genetic material. The rising burden of genetic disorders can be attributed to several factors, including advancements in medical technology, changes in demographics, and improvements in diagnosis and awareness. Exondys 51 (eteplirsen) treats genetic disorders by enabling exon 51 skipping in the dystrophin gene, allowing the production of a functional, though shortened, dystrophin protein to slow muscle degeneration. For instance, in July 2024, according to the National Health Service, a UK-based government department, approximately 70,000 individuals are affected by muscular dystrophy (MD) or a related condition in the UK, with Duchenne MD being the most prevalent form. Each year, around 100 boys are diagnosed with Duchenne MD, and approximately 2,500 people in the UK are living with the condition at any given time. Therefore, the rising burden of genetic disorders is driving the growth of the exondys 51 market.
What are the fastest-growing segments in the exondys 51 market forecast period?
The exondys 51 market covered in this report is segmented –
1) By Clinical Indication: Relapsing-Remitting Multiple Sclerosis (RRMS), Secondary Progressive Multiple Sclerosis (SPMS), Other Multiple Sclerosis Forms
2) By Distribution Channel: Hospital Pharmacies, Specialty Pharmacies, Online Pharmacies
3) By Application: Subcutaneous Injection, Long-Term Disease Management, Prophylactic Use
View The Full Market Report:
https://www.thebusinessresearchcompany.com/report/exondys-51-global-market-report
How are emerging trends transforming the exondys 51 market dynamics?
The key trend in the exondys 51 market is obtaining regulatory approvals to expand its use to a broader range of Duchenne muscular dystrophy (DMD) patients, including those with different genetic mutations, and to improve accessibility in global markets. Regulatory approvals refer to the official authorization granted by health authorities, such as the FDA or EMA, allowing a drug or treatment to be marketed and used based on its proven safety and efficacy. For instance, Sarepta Therapeutics, a US-based biotechnology company, received FDA approval for two significant gene therapies for duchenne muscular dystrophy (DMD). The expanded approval of Elevidys allows its use in both ambulatory and non-ambulatory patients aged four years and older with confirmed DMD gene mutations, making it the first gene therapy approved for this condition. Additionally, Amondys 45 has been approved for patients with specific mutations in the dystrophin gene, targeting about 8% of DMD cases. These approvals highlight Sarepta’s commitment to advancing treatment options for individuals affected by this debilitating disease.
Which major players hold significant market share in the exondys 51 sector?
Major companies operating in the exondys 51 market include Sarepta Therapeutics
Which regional segments are forecasted to witness the fastest growth in the exondys 51 market?
North America was the largest region in the exondys 51 market in 2024. Europe is expected to be the fastest-growing region in the forecast period. The regions covered in the exondys 51 market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.
How Can Companies Use The Exondys 51 Market Report to Drive Business Results?
This report provides actionable insights tailored for business use—not academic analysis. Companies can leverage the data to:
• Time market entry or expansion using growth forecasts and CAGR trends.
• Develop competitive products by tracking key technology shifts and user preferences.
• Tailor regional strategies with in-depth geographic data and local market dynamics.
• Benchmark and plan partnerships using competitive landscape insights.
Purchase The Report And Get A Swift Delivery:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=20071
Need Customized Data On Exondys 51 Market?
For companies needing more tailored intelligence, The Business Research Company offers customized consulting and data services. Whether you’re entering new regions, launching innovative products, or assessing M&A opportunities, our experts can develop actionable insights specific to your business objectives.
Request Customized Data:
https://www.thebusinessresearchcompany.com/customise?id=20071&type=smp
About The Business Research Company:
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead.
Our flagship product, the Global Market Model, is a premier market intelligence platform delivering comprehensive and updated forecasts to support informed decision-making.
Contact Us:
The Business Research Company
https://thebusinessresearchcompany.com/
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293
Email: info@tbrc.info
Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
